NURS6521 / NURS 6521 Final Exam (Latest) Advanced
Pharmacology – Walden University Actual Exam – Complete
Questions and Answers with Detailed Rationales – Pass
Guaranteed – A+ Graded
Foundations: Pharmacokinetics, Pharmacodynamics & Principles of
Prescribing
Q1: A patient with normal renal function is started on a new medication with a half-life
of 8 hours. Approximately how long will it take to reach steady-state plasma
concentration?
A. 8 hours
B. 16 hours
C. 32-40 hours [CORRECT]
D. 80 hours
Correct Answer: C
Rationale: The best answer is C. This is correct because steady state is generally
reached after 4-5 half-lives, so with an 8-hour half-life you're looking at 32-40 hours. This
is why we don't judge efficacy or toxicity of most drugs before they've had time to build
up to their steady-state concentration.
Q2: A patient of Asian ancestry is being considered for carbamazepine therapy for
trigeminal neuralgia. Before initiating treatment, the prescriber should order:
A. HLA-B5701 screening
B. HLA-B1502 screening [CORRECT]
C. TPMT genotyping
,D. CYP2D6 genotyping
Correct Answer: B
Rationale: The best answer is B. This is correct because HLA-B1502 is strongly
associated with Stevens-Johnson syndrome and toxic epidermal necrolysis in patients of
Asian ancestry treated with carbamazepine. The FDA recommends screening before
initiating therapy in these populations. HLA-B5701 is for abacavir hypersensitivity, TPMT
is for thiopurines, and CYP2D6 testing wouldn't catch this specific severe cutaneous
reaction.
Q3: A drug with a high volume of distribution (Vd > 5 L/kg) is most likely:
A. Hydrophilic and confined to the plasma compartment
B. Lipophilic and extensively distributed into tissues [CORRECT]
C. Highly protein-bound with minimal tissue penetration
D. Excreted unchanged by the kidneys
Correct Answer: B
Rationale: The best answer is B. This is correct because a high Vd indicates the drug
distributes extensively beyond plasma into tissues—think fat, muscle, and other body
compartments. Lipophilic drugs do this readily, while hydrophilic drugs tend to stay in
the plasma and extracellular fluid, giving them a lower Vd. This matters for dosing in
obesity and for understanding why some drugs have long half-lives despite rapid
metabolism.
Q4: A patient on phenytoin has a total serum level of 18 mcg/mL but is exhibiting signs
of toxicity. Albumin is 2.8 g/dL. The prescriber should recognize that:
A. The level is therapeutic and symptoms are unrelated
B. The free fraction is increased due to hypoalbuminemia, making the effective level
toxic [CORRECT]
C. Phenytoin levels are not affected by albumin
D. The patient needs a higher dose to achieve therapeutic effect
,Correct Answer: B
Rationale: The best answer is B. This is correct because phenytoin is highly
protein-bound, and when albumin is low, more drug exists in the free, unbound,
pharmacologically active form. A total level of 18 might look therapeutic, but the free
phenytoin level could be well above the therapeutic range of 1-2 mcg/mL, explaining the
toxicity. Always consider protein binding and albumin status when interpreting levels for
highly bound drugs.
Q5: A prodrug requires which pharmacokinetic process to become pharmacologically
active?
A. Excretion
B. Metabolism [CORRECT]
C. Distribution
D. Absorption
Correct Answer: B
Rationale: The best answer is B. This is correct because a prodrug is administered in an
inactive form and must undergo metabolic conversion—usually in the liver—to its active
metabolite. Clopidogrel is a classic example; it requires CYP2C19 metabolism to
become active. If a patient is a CYP2C19 poor metabolizer, they get subtherapeutic
activation and increased cardiovascular risk.
Q6: A patient taking clopidogrel after coronary stenting has a recurrent cardiovascular
event. Genetic testing reveals CYP2C19 poor metabolizer status. The prescriber should
consider switching to:
A. A higher dose of clopidogrel
B. Prasugrel or ticagrelor [CORRECT]
C. Aspirin alone
D. Warfarin
Correct Answer: B
, Rationale: The best answer is B. This is correct because clopidogrel is a prodrug
requiring CYP2C19 activation, and poor metabolizers can't convert it efficiently to its
active form. Prasugrel and ticagrelor don't rely on CYP2C19 metabolism and provide
more reliable antiplatelet effect in these patients. Simply increasing clopidogrel dose
doesn't overcome the metabolic limitation.
Q7: A patient on warfarin has an INR of 6.2 without bleeding. The prescriber recently
started the patient on amiodarone for atrial fibrillation. The most appropriate
management is:
A. Continue warfarin at current dose and recheck INR in one week
B. Hold 1-2 doses of warfarin, reduce maintenance dose, and recheck INR in 2-3 days
[CORRECT]
C. Administer vitamin K 5 mg orally immediately
D. Switch to a DOAC immediately
Correct Answer: B
Rationale: The best answer is B. This is correct because amiodarone is a potent
CYP2C9 and CYP1A2 inhibitor that significantly increases warfarin levels. Without
active bleeding, you don't need vitamin K or a switch to DOAC—just hold a dose or two,
reduce the maintenance dose by about 25-50%, and monitor closely. Amiodarone's
interaction takes time to develop and resolve, so frequent INR checks are essential.
Q8: A patient with chronic pain is prescribed an extended-release opioid. The prescriber
should also provide:
A. A bowel regimen including a stimulant laxative [CORRECT]
B. An antiemetic to be taken only when nausea occurs
C. A benzodiazepine for breakthrough anxiety
D. An antihistamine for pruritus prevention
Correct Answer: A
Rationale: The best answer is A. This is correct because opioid-induced constipation is
so predictable that prophylactic bowel management is standard of care, not reactive
Pharmacology – Walden University Actual Exam – Complete
Questions and Answers with Detailed Rationales – Pass
Guaranteed – A+ Graded
Foundations: Pharmacokinetics, Pharmacodynamics & Principles of
Prescribing
Q1: A patient with normal renal function is started on a new medication with a half-life
of 8 hours. Approximately how long will it take to reach steady-state plasma
concentration?
A. 8 hours
B. 16 hours
C. 32-40 hours [CORRECT]
D. 80 hours
Correct Answer: C
Rationale: The best answer is C. This is correct because steady state is generally
reached after 4-5 half-lives, so with an 8-hour half-life you're looking at 32-40 hours. This
is why we don't judge efficacy or toxicity of most drugs before they've had time to build
up to their steady-state concentration.
Q2: A patient of Asian ancestry is being considered for carbamazepine therapy for
trigeminal neuralgia. Before initiating treatment, the prescriber should order:
A. HLA-B5701 screening
B. HLA-B1502 screening [CORRECT]
C. TPMT genotyping
,D. CYP2D6 genotyping
Correct Answer: B
Rationale: The best answer is B. This is correct because HLA-B1502 is strongly
associated with Stevens-Johnson syndrome and toxic epidermal necrolysis in patients of
Asian ancestry treated with carbamazepine. The FDA recommends screening before
initiating therapy in these populations. HLA-B5701 is for abacavir hypersensitivity, TPMT
is for thiopurines, and CYP2D6 testing wouldn't catch this specific severe cutaneous
reaction.
Q3: A drug with a high volume of distribution (Vd > 5 L/kg) is most likely:
A. Hydrophilic and confined to the plasma compartment
B. Lipophilic and extensively distributed into tissues [CORRECT]
C. Highly protein-bound with minimal tissue penetration
D. Excreted unchanged by the kidneys
Correct Answer: B
Rationale: The best answer is B. This is correct because a high Vd indicates the drug
distributes extensively beyond plasma into tissues—think fat, muscle, and other body
compartments. Lipophilic drugs do this readily, while hydrophilic drugs tend to stay in
the plasma and extracellular fluid, giving them a lower Vd. This matters for dosing in
obesity and for understanding why some drugs have long half-lives despite rapid
metabolism.
Q4: A patient on phenytoin has a total serum level of 18 mcg/mL but is exhibiting signs
of toxicity. Albumin is 2.8 g/dL. The prescriber should recognize that:
A. The level is therapeutic and symptoms are unrelated
B. The free fraction is increased due to hypoalbuminemia, making the effective level
toxic [CORRECT]
C. Phenytoin levels are not affected by albumin
D. The patient needs a higher dose to achieve therapeutic effect
,Correct Answer: B
Rationale: The best answer is B. This is correct because phenytoin is highly
protein-bound, and when albumin is low, more drug exists in the free, unbound,
pharmacologically active form. A total level of 18 might look therapeutic, but the free
phenytoin level could be well above the therapeutic range of 1-2 mcg/mL, explaining the
toxicity. Always consider protein binding and albumin status when interpreting levels for
highly bound drugs.
Q5: A prodrug requires which pharmacokinetic process to become pharmacologically
active?
A. Excretion
B. Metabolism [CORRECT]
C. Distribution
D. Absorption
Correct Answer: B
Rationale: The best answer is B. This is correct because a prodrug is administered in an
inactive form and must undergo metabolic conversion—usually in the liver—to its active
metabolite. Clopidogrel is a classic example; it requires CYP2C19 metabolism to
become active. If a patient is a CYP2C19 poor metabolizer, they get subtherapeutic
activation and increased cardiovascular risk.
Q6: A patient taking clopidogrel after coronary stenting has a recurrent cardiovascular
event. Genetic testing reveals CYP2C19 poor metabolizer status. The prescriber should
consider switching to:
A. A higher dose of clopidogrel
B. Prasugrel or ticagrelor [CORRECT]
C. Aspirin alone
D. Warfarin
Correct Answer: B
, Rationale: The best answer is B. This is correct because clopidogrel is a prodrug
requiring CYP2C19 activation, and poor metabolizers can't convert it efficiently to its
active form. Prasugrel and ticagrelor don't rely on CYP2C19 metabolism and provide
more reliable antiplatelet effect in these patients. Simply increasing clopidogrel dose
doesn't overcome the metabolic limitation.
Q7: A patient on warfarin has an INR of 6.2 without bleeding. The prescriber recently
started the patient on amiodarone for atrial fibrillation. The most appropriate
management is:
A. Continue warfarin at current dose and recheck INR in one week
B. Hold 1-2 doses of warfarin, reduce maintenance dose, and recheck INR in 2-3 days
[CORRECT]
C. Administer vitamin K 5 mg orally immediately
D. Switch to a DOAC immediately
Correct Answer: B
Rationale: The best answer is B. This is correct because amiodarone is a potent
CYP2C9 and CYP1A2 inhibitor that significantly increases warfarin levels. Without
active bleeding, you don't need vitamin K or a switch to DOAC—just hold a dose or two,
reduce the maintenance dose by about 25-50%, and monitor closely. Amiodarone's
interaction takes time to develop and resolve, so frequent INR checks are essential.
Q8: A patient with chronic pain is prescribed an extended-release opioid. The prescriber
should also provide:
A. A bowel regimen including a stimulant laxative [CORRECT]
B. An antiemetic to be taken only when nausea occurs
C. A benzodiazepine for breakthrough anxiety
D. An antihistamine for pruritus prevention
Correct Answer: A
Rationale: The best answer is A. This is correct because opioid-induced constipation is
so predictable that prophylactic bowel management is standard of care, not reactive
